Search Result

Results for "

Hsp90 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HSP (214) Hsp-targeting Chimeras (1) ADC Payload (4) Akt (14) AMPK (1) Amyloid-β (1) Androgen Receptor (3) Antibiotic (13) APC (1) Apoptosis (63) ATP-binding cassette (ABC) transporters (1) Aurora Kinase (1) Autophagy (21) Bacterial (13) Bcl-2 Family (1) Bcr-Abl (3) Beta-lactamase (2) c-Kit (1) c-Myc (4) Casein Kinase (1) Caspase (4) Cathepsin (1) CD47 (1) CDK (15) Cholinesterase (ChE) (1) Cytochrome P450 (1) DNA/RNA Synthesis (5) Drug Derivative (1) Drug Intermediate (2) Drug Metabolite (2) Early 2 Factor (E2F) (1) EGFR (9) Enterovirus (1) Environmental Pollutants (1) Epigenetic Reader Domain (3) ERK (6) Estrogen Receptor/ERR (7) FABP (1) FAK (2) FKBP (2) Fungal (7) GLUT (1) GSK-3 (1) HDAC (8) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) Histone Methyltransferase (1) HIV (1) HSV (2) IAP (1) Influenza Virus (3) Integrin (1) Interleukin Related (3) Isotope-Labeled Compounds (4) JNK (4) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (1) MHC (1) Microtubule/Tubulin (3) Mitochondrial Metabolism (2) Mitophagy (3) Molecular Glues (1) Monoamine Oxidase (2) mTOR (4) Na+/K+ ATPase (1) NADPH Oxidase (1) Necroptosis (2) NF-κB (5) NO Synthase (2) Orthopoxvirus (3) p38 MAPK (2) Parasite (2) PARP (2) PD-1/PD-L1 (2) PDGFR (1) PDHK (2) PERK (2) PI3K (4) Potassium Channel (4) PPAR (1) PROTACs (4) Raf (2) Ras (2) Reactive Oxygen Species (ROS) (6) Reference Standards (15) RIP kinase (2) Sirtuin (1) SOD (1) STAT (3) Survivin (1) Tau Protein (1) Thrombopoietin Receptor (1) TNF Receptor (1) Topoisomerase (1) ULK (1) VEGFR (4) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (198) Cardiovascular Disease (3) Endocrinology (3) Infection (36) Inflammation/Immunology (27) Metabolic Disease (9) Neurological Disease (20)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (2)

233

Inhibitors & Agonists

Fluorescent Dyes

Peptides

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Hsp-targeting Chimeras HSP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10211

Tanespimycin 65+ Cited Publications 17-AAG; NSC 330507; CP 127374	HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (17-AAG) is a potent *HSP90* inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-10215

Luminespib 20+ Cited Publications VER-52296; AUY922; NVP-AUY922	HSP Autophagy Apoptosis	Cancer
Luminespib (VER-52296) is a potent *HSP90* inhibitor with IC₅₀s of 7.8 and 21 nM for HSP90α and HSP90β, respectively .

HY-15190

NVP-HSP990 4 Publications Verification Hsp-990	HSP Apoptosis	Cancer
NVP-HSP990 is a potent, selective and orally active *Hsp90* inhibitor, with IC₅₀ values of 0.6, 0.8, and 8.5 nM for Hsp90α, Hsp90β, and Grp94, respectively.

HY-12024

Alvespimycin hydrochloride 15+ Cited Publications 17-DMAG hydrochloride; KOS-1022 hydrochloride; BMS 826476	HSP Apoptosis	Cancer
Alvespimycin hydrochloride (17-DMAG hydrochloride; KOS-1022; BMS 826476) is a potent inhibitor of *Hsp90, binding to Hsp90* with EC₅₀ of 62±29 nM.

HY-10389

Alvespimycin 15+ Cited Publications 17-DMAG; KOS-1022; NSC 707545	HSP	Cancer
Alvespimycin (17-DMAG) is a potent inhibitor of *Hsp90, binding to Hsp90* with an EC₅₀ of 62 nM.

HY-10210

Retaspimycin Hydrochloride 5 Publications Verification IPI-504	HSP	Cancer
Retaspimycin Hydrochloride is a potent inhibitor of *Hsp90* with EC₅₀s of 119 nM for both Hsp90 and Grp9.

HY-10214

SNX-2112 3 Publications Verification PF-04928473	HSP Autophagy	Cancer
SNX-2112 (PF 04928473) is an orally active *Hsp90* inhibitor, with a K_d of 16 nM for *Hsp90* and IC₅₀s of 30 nM, 30 nM for Hsp90 α and Hsp90 β, also induces Her-2 degradation, and inhibits Grp94 and Trap-1, with IC₅₀s of 10 nM, 4.275 μM and 0.862 μM, respectively . SNX-2112 (PF 04928473) binds Hsp90 isoforms Hsp90α, Hsp90β and Hsp90b1/Grp94 with K_ds of 4 nM, 6 nM and 484 nM, respectively .

HY-13469

Debio 0932 5+ Cited Publications CUDC-305	HSP	Cancer
Debio 0932 (CUDC-305) is an orally active *HSP90* inhibitor, with IC₅₀s of 100 and 103 nM for HSP90α and HSP90β, respectively .

HY-107577

Gedunin	HSP	Infection Inflammation/Immunology Cancer
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of *HSP90* in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on *HSP90* protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-130851

HS-27	HSP	Cancer
HS-27, a fluorescently-tethered *Hsp90* inhibitor, assays surface Hsp90 expression on intact tissue specimens. HS-27 is made up of the core elements of SNX-5422, an Hsp90 inhibitor, tethered via a PEG linker to a fluorescein derivative (fluorescein isothiocyanate or FITC), that binds to ectopically expressed Hsp90. HS-27 has potential use in a see-and-treat paradigm in breast cancer .

HY-15986

VER-49009 CCT 129397	HSP	Cancer
VER-49009 is a *Hsp90* inhibitor, with an IC₅₀ of 25 nM and a K_d of 78 nM.

HY-15984

VER-50589 1 Publications Verification	HSP Apoptosis	Cancer
VER-50589 is a *Hsp90* inhibitor, with an IC₅₀ of 21 nM and a K_d of 4.5 nM.

HY-139301

DDO-5936 1 Publications Verification	HSP	Cancer
DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer .

HY-148215A

Hsp90-IN-17 hydrochloride	HSP	Neurological Disease Cancer
Hsp90-IN-17 (Example 5) hydrochloride is an *HSP90* inhibitor that can be used in the study of proliferative diseases, such as cancer and neurodegenerative diseases .

HY-119906

Conglobatin FW-04-806	HSP Apoptosis	Cancer
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-119046

SNX-0723 2 Publications Verification	HSP Parasite	Infection
SNX-0723 is a potent *Hsp90* Inhibitor with anti-Plasmodium activity. SNX-0723 shows high binding affinity for HsHsp90 and PfHsp90 with K_is of 4.4 and 47 nM, respectively. SNX-0723 inhibits liver-stage P. berghei ANKA parasites with the EC₅₀ of 3.3 μM .

HY-133705

Geldanamycin-FITC 1 Publications Verification	HSP	Others
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 (Ex/Em = 488/515 nm) .

HY-W107935

Hsp90-IN-37	HSP	Cancer
Hsp90-IN-37 (Z-2) is a heat shock protein 90 (Hsp90) inhibitor that inhibits Hsp90 enzymatic activity by 69%. Hsp90-IN-37 has antitumor activity .

HY-11038D

Zelavespib formic 10+ Cited Publications PU-H71 formic	HSP	Cancer
Zelavespib formic (PU-H71 formic) is a potent *Hsp90* inhibitor with an IC₅₀ value of 51 nM for *Hsp90* in MDA-MB-468 cells .

HY-149891

HSP90-IN-23	HSP	Cancer
HSP90-IN-23 (Comp 12-1) is an inhibitor of heat shock protein 90(HSP90) with an IC₅₀ of 9 nM. HSP90-IN-23 induces apoptosis of tumor cells and arrests the tumor cell cycle in G0/G1 phase. HSP90-IN-23 can be used for cancer research .

HY-111414

Hsp90-Cdc37-IN-1	HSP	Cancer
Hsp90-Cdc37-IN-1 is an *Hsp90-Cdc37* interaction disruptor that inhibit cell migration and reverse agent resistance, with an IC₅₀ of 140 nM.

HY-151335

KU-177	HSP	Cancer
KU-177 is a potent inhibitor of *Hsp90* ATPase homologue 1 (Aha1), ablates Aha1-driven enhancement of Hsp90-dependent tau aggregation. KU-177 also disrupts *Aha1/Hsp90* interactions (IC₅₀=4.08 μM) without inhibition of Hsp90’s ATPase activity. KU-177 can be used for tauopathies research .

HY-115781

DN401 1 Publications Verification Panvotinib-401; Pan-401	HSP	Cancer
DN401 is a potent TRAP1 inhibitor with an IC₅₀ of 79 nM. DN401 shows a weak inhibition of *Hsp90* (IC₅₀ of 698 nM). DN401 inactivates mitochondrial TRAP1 and has potent anticancer activities .

HY-153588

HSP90-IN-22	HSP	Cancer
HSP90-IN-22 (Compound 35) is an Hsp90 inhibitor with antiproliferative properties on cells with IC₅₀ values of 3.65 μM for MCF7 breast cancer cells and 2.71 μM for SKBr3 breast cancer cells, respectively.

HY-117395

PU-H54	HSP	Cancer
PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-152184

SEW84 SEW04784	HSP	Metabolic Disease
SEW84 is an inhibitor of Aha1-stimulated Hsp90 (ASH) ATPase activity. SEW84 inhibits Aha1-stimulated Hsp90 (ASH) activity with an IC₅₀ value of 0.3 μM. SEW84 can be used in the study of protein deposition diseases .

HY-146325

HSP90-IN-11	HSP	Cancer
HSP90-IN-11 (Compound 12c) is a potent inhibitor of *HSP90. HSP90-IN-11* displays potent HSP90α inhibition comparable to AUY-922 (Luminespib). HSP90-IN-11 shows significant antiproliferative activity in CRC and NSCLC cells in a double digit nM range. HSP90-IN-11 leads to rapid degradation of client proteins EGFR and Akt in NSCLC cells. HSP90-IN-11 induces significant accumulation of a sub-G1 phase population .

HY-144650

Hsp90-Cdc37-IN-3	Apoptosis HSP	Cancer
Hsp90-Cdc37-IN-3 (Compound 9) is a novel celastrol−imidazole derivative with anticancer activity. Hsp90-Cdc37-IN-3 inhibits *Hsp90−Cdc37* by covalent-binding, and induces apoptosis .

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent *HSP90* pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .

HY-176279

Hsp90-IN-42	HSP	Cancer
Hsp90-IN-42 (Compound 13l) is a potent heat shock protein 90 (Hsp90) inhibitor (IC₅₀=15.65 nM). Hsp90-IN-42 reduces the stability of the epidermal growth factor receptor (EGFR), suppressing the activation of the EGFR-Akt signaling pathway, inducing G0/G1 phase arrest in colorectal cancer cells (such as HT-29 cells), and slightly triggering apoptosis. Hsp90-IN-42 also inhibits cell proliferation and migration by down-regulating the expression of CDK12, CDK13, and Bcl-2 proteins, and up-regulating the expression of Bax protein. Hsp90-IN-42 is promising for research of colorectal cancer .

HY-10211R

Tanespimycin (Standard) 17-AAG (Standard); NSC 330507 (Standard); CP 127374 (Standard)	Reference Standards HSP Autophagy Mitophagy Bacterial Apoptosis Antibiotic	Infection Cancer
Tanespimycin (Standard) is the analytical standard of Tanespimycin. This product is intended for research and analytical applications. Tanespimycin (17-AAG) is a potent *HSP90* inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-162589

Lw13	PROTACs HSP Apoptosis	Cancer
Lw13 is a *Hsp90*-targeting PROTAC and achieves maximum degradation at a concentration of 0.05 μM in Siha cells. Lw13 induces cell apoptosis and exhibits potent anti-tumor activity both in vitro and in vivo(Sturcture Note:(Blue: Cereblon ligand (HY-A0003), Black: linker；Pink: Hsp90 inhibitor SNX-5422 (HY-10213)) .

HY-144694

HDAC/HSP90-IN-3	HSP HDAC Fungal	Infection
HDAC/HSP90-IN-3 (compound J5) is a potent and selective fungal *Hsp90* and HDAC dual inhibitor, with IC₅₀ values of 0.83 and 0.91 μM, respectively. HDAC/HSP90-IN-3 shows antifungal activity against azole resistant C. albicans. HDAC/HSP90-IN-3 can suppress important virulence factors and down-regulate drug-resistant genes ERG11 and CDR1 .

HY-174476

HSP90i	HSP Drug Intermediate	Cancer
HSP90i is a *HSP90* inhibitor. HSP90i can be used as a drug intermediate to synthesize LYTACs, such as dPDL1-4 (HY-174468) .

HY-147125

DDO-6600	HSP Akt CDK Raf Apoptosis	Cancer
DDO-6600 is a covalent *Hsp90* inhibitor. DDO-6600 disrupts the interaction between Hsp90 and its co-chaperone protein Cdc37, thereby inducing the degradation of kinase client proteins (such as AKT, CDK4, c-Raf). DDO-6600 has inhibitory activity against various cancer cells. DDO-6600 inhibits the migration and invasion of HCT-116 cells, and induces cell cycle arrest and apoptosis. DDO-6600 significantly inhibits tumor growth in the HCT-116 xenograft tumor model. DDO-6600 can be used for research on colorectal cancer .

HY-133571

Aminohexylgeldanamycin AHGDM	HSP ADC Payload	Cancer
Aminohexylgeldanamycin (AHGDM), a Geldanamycin derivative, is a potent *HSP90* inhibitor. Aminohexylgeldanamycin shows antiangiogenic and antitumor activities .

HY-170895

Hsp90-IN-38	HSP Na+/K+ ATPase	Cancer
Hsp90-IN-38 (compound 20m) is a HSP90 (heat shock protein) inhibitor. Hsp90-IN-38 exhibits strong *HSP90* binding affinity with a K_d of 87 nM. Hsp90-IN-38 inhibits ATPase with an IC₅₀ of 0.13 μM. Hsp90-IN-38 inhibits HCT116, MCF-7, SKBr3, K562 and A549 cells with IC₅₀s of 0.187, 0.072, 0.105, 0.403 and 031 μM, respectively .

HY-170326

HSP90-IN-35	Ligands for Target Protein for PROTAC HSP	Cancer
Hsp90-in-35 (Compound 379) is an inhibitor of *Hsp90. The IC₅₀* of HSP90-IN-35 for Her2 is between 0.05 and 0.5 μM. HSP90-IN-35 has antitumor activity. HSP90-IN-35 can be used to synthesize PROTAC (HY-153881) .

HY-144724

HSP90-IN-10	HSP Apoptosis	Cancer
HSP90-IN-10 (Compound 16s) is a potent inhibitor of *HSP90. HSP90-IN-10* exhibits high antiproliferative potency against HCC1954 breast cancer cells with the IC₅₀ value of 6 µM. HSP90-IN-10 does not inhibit the growth of normal epithelial cells. HSP90-IN-10 also induces apoptosis .

HY-150655

Hsp90-IN-15	HSP	Cancer
Hsp90-IN-15 is an *Hsp90* inhibitor with anticancer activity. Hsp90-IN-15 induces cell apoptosis, arrests the cell cycle at S phase and decreases the expression level of *Hsp90* in Hela cell .

HY-171755

Hsp90-IN-40	HSP	Cancer
Hsp90-IN-40 (Compound 15b) is a heat shock protein 90 (Hsp90) C-terminal inhibitor. Hsp90-IN-40 exhibits antiproliferative activity against SKBr3 and MCF-7 breast cancer cells (IC₅₀ of 2.57 µM and 2.43 µM, respectively). Hsp90-IN-40 inhibits cancer cell growth by inhibiting the Hsp90 C-terminal function, leading to Hsp90-dependent protein degradation. Hsp90-IN-40 can be used in breast cancer research .

HY-113574

HSP90-IN-29	HSP	Cancer
HSP90-IN-29 (Compound 13), a benzoxazole derivative, is a potent and selective *HSP-90* inhibitor with an IC₅₀ value of 30 nM. HSP90-IN-29 has antitumor activity .

HY-148963

HSP90-IN-20	HSP	Cancer
HSP90-IN-20 (compound 78p) is a potent *HSP90* inhibitor with an IC₅₀ of ≤10 μM. HSP90-IN-20 has the potential for cancers research .

HY-145814

HSP90-IN-9	HSP Fungal	Infection
HSP90-IN-9 is a potent and selective *HSP90* inhibitor. HSP90-IN-9 displays a fungicidal effect in a dose-dependent manner. HSP90-IN-9 inhibits fungal biofilm formation and fungal morphological changes after being combined with FLC. HSP90-IN-9 recovers FLC resistance by down-regulating the expression of related genes (ERG11, CDR1 and CDR2) .

HY-179377

Aha1/Hsp90-IN-2	HSP Tau Protein	Neurological Disease
Aha1/Hsp90-IN-2 is a selective inhibitor of the *Hsp90/Aha1* interaction, with its IC₅₀ being 1.46 μM. Aha1/Hsp90-IN-2 inhibits the activation of Hsp90 ATPase activity mediated by Aha1 by specifically blocking the binding of Hsp90 to Aha1, thereby reducing tau protein aggregation. Aha1/Hsp90-IN-2 can be used for the study of neurodegenerative diseases, such as Alzheimer's disease .

HY-177042

Hsp90-IN-41	HSP Fungal	Infection Cancer
Hsp90-IN-41 (Compound C1) is an inhibitor of *Hsp90* (IC₅₀ = 0.044 μM). Hsp90-IN-41 exhibits antifungal and antitumor (IC₅₀ = 0.049 μM) activities in vitro .

HY-151137

HSP90/mTOR-IN-1	mTOR HSP Apoptosis Autophagy	Cancer
HSP90/mTOR-IN-1 is a potent and orally active *Hsp90* and mTOR inhibitor with IC₅₀ values of 69 nM and 29 nM, respectively. HSP90/mTOR-IN-1 suppresses the proliferation of SW780 cells through the over-activation of the PI3K/AKT/mTOR pathway. HSP90/mTOR-IN-1 induces apoptosis and autophagy via selective Hsp90 and mTOR inhibition. HSP90/mTOR-IN-1 also has considerable in vivo anti-tumor activity. HSP90/mTOR-IN-1 can be used for researching bladder cancer .

HY-170910

Hsp90-IN-39	HSP	Cancer
Hsp90-IN-39 (Compound 16t) is a *HSP90* inhibitor with notable selectivity for the *HSP90α* isoform. Hsp90-IN-39 demonstrates significant antiproliferative activity in various cancer cell lines, including MCF-7, HCT116, SKBr3, K562, and A549. Hsp90-IN-39 holds potential for cancer research .

HY-168205

HSP90-IN-33	HSP Apoptosis	Cancer
HSP90-IN-33 (compound 24e) is a potent *Hsp90* inhibitor with K_d values of ≥200, 7.3 µM for Hsp90α, Hsp90β, respectively. HSP90-IN-33 induces apoptosis and cell cycle arrest at G0/G1 phase. HSP90-IN-33 decreases the protein expression of ERα, CDK4 and Akt .

Cat. No.	Product Name	Type

HY-133705

Geldanamycin-FITC 1 Publications Verification	Fluorescent Dyes
Geldanamycin-FITC, a Geldanamycin fluorescent probe, can be used in a fluorescence polarization assay for HSP90 inhibitors. Geldanamycin-FITC also can be used for detection of cell surface HSP90 (Ex/Em = 488/515 nm) .

HY-122878

HS-131	Fluorescent Dyes
HS-131, a near infrared dye tethered *Hsp90* inhibitor, is able to detect oncogene-driven breast cancers, including multiple different molecular subtypes of human breast cancers .

Cat. No.	Product Name	Target	Research Area

HY-P10371

PKHB1 txCD47	Reactive Oxygen Species (ROS) Thrombopoietin Receptor Mitochondrial Metabolism HSP HSV CD47	Infection Inflammation/Immunology Cancer
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and *HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8* ⁺T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15230

Geldanamycin Maximum Cited Publications 40 Publications Verification	Infection Quinones Structural Classification Microorganisms Classification of Application Fields Benzene Quinones Inflammation/Immunology Disease Research Fields Source Classification	HSP Bacterial Influenza Virus Antibiotic
Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-B0425A

Novobiocin sodium 10+ Cited Publications Albamycin sodium; Cathomycin sodium	Microorganisms Anti-inflammation/Immunoregulatory Classification of Application Fields Antibiotics Antiviral Antibacterial Disease Research Disease Research Fields Other Antibiotics Source Classification Cancer	Bacterial Antibiotic Orthopoxvirus Apoptosis DNA/RNA Synthesis HSP
Novobiocin (Albamycin) sodium is a potent and orally active antibiotic. Novobiocin sodium also is a DNA gyrase inhibitor and a heat shock protein 90 (Hsp90) antagonist. Novobiocin sodium has the potential for the research of highly beta-lactam-resistant pneumococcal infections. Novobiocin sodium shows anti-orthopoxvirus activity .

HY-N6769

Radicicol 4 Publications Verification Monorden	Antifungal Classification of Application Fields Marine natural products Anti-parasitic Disease Research Infection Microorganisms Macrolide Antibiotics Antibiotics Phenols Polyphenols Marine microorganism Disease Research Fields Source Classification	HSP Bacterial Antibiotic Parasite
Radicicol is an inhibitor of *Hsp90* with an IC₅₀ value < 1 μM, and leads to proteasomal degradation . Radicicol exhibits inhibition on PDK with IC₅₀s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB . Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC₅₀ value of 16.04 μM .

HY-N1934

Dihydroberberine	Cardiovascular Disease Alkaloids other families Classification of Application Fields Plants Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Source Classification	Potassium Channel HSP
Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-N1073

Wighteone 1 Publications Verification 6-Isopentenylgenistein; Erythrinin B	Leguminosae Genista ephedroides DC. Plants Isoflavones Source Classification	Apoptosis EGFR HSP ERK Akt
Wighteone (6-Isopentenylgenistein; Erythrinin B) is a prenylated isoflavone that acts as a HSP90/EGFR ^L858R/T790M inhibitor and antifungal agent. Wighteone reduces the expression level of *HSP90, blocks EGF-induced phosphorylation of EGFR, and thereby inhibits* the downstream ERK and AKT signaling pathways. Wighteone induces cell cycle redistribution, inhibits proliferation and triggers apoptosis in cancer cells. Wighteone can be isolated from Erythrina suberosa, and can also be induced to synthesize in Lotus japonicus under specific conditions. Wighteone can be used to study HER2-positive breast cancer, leukemia, non-small cell lung cancer with EGFR ^L858R/T790M mutation, and fungal infections .

HY-107577

Gedunin	Infection Triterpenes other families Classification of Application Fields Terpenoids Plants Inflammation/Immunology Disease Research Fields Source Classification	HSP
Gedunin is a limonoid with anti-cancer, anti-viral, anti-inflammatory and insecticidal activities. Gedunin acts as a potent *Hsp90* inhibitor and induces the degradation of Hsp90-dependent client proteins. Geduni may obstructs the entry of SARS-CoV-2 virus into human host cells and can be used for COVID-19 research .

HY-N1455

Falcarinol 1 Publications Verification Panaxynol; Carotatoxin	Natural Products Classification of Application Fields Ambrosia psilostachya DC. Umbelliferae Plants Disease Research Fields Source Classification Cancer	HSP Apoptosis
Falcarinol (Panaxynol) is a natural, orally active *Hsp90* inhibitor targeting both the N-terminal and C-terminal of Hsp90 with limited toxicities. Falcarinol (Panaxynol) induces apoptosis . Falcarinol is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B1434

7-Aminocephalosporanic acid 2 Publications Verification 7-ACA	Infection Classification of Application Fields Disease Research Fields	Beta-lactamase Bacterial Antibiotic
7-aminocephalosporanic acid (7-ACA) is a *HSP90β* inhibitor and an antibiotic. 7-Aminocephalosporanic acid is the core chemical structure of the synthesis of cephalosporin antibiotics and an effective β-lactamase inhibitor .

HY-N2445

Flavokawain C 4 Publications Verification	Structural Classification Classification of Application Fields Piperaceae Plants Chalcones Flavonoids other families Phenols Polyphenols Piper methysticum G.Forst. Disease Research Fields Source Classification Cancer	Apoptosis Akt JNK PERK Caspase PARP MDM-2/p53 IAP Reactive Oxygen Species (ROS) SOD FABP Autophagy AMPK mTOR GLUT EGFR PI3K HSP VEGFR FAK
Flavokawain C is an orally active natural chalcone. Flavokawain C inhibits the proliferation of various cancer cells. Flavokawain C upregulates GADD153 in cancer cells, inhibits the phosphorylation of Akt and JNK, suppresses early ERK phosphorylation, activates late ERK phosphorylation, activates caspase related subtypes, induces PARP-1 cleavage, causes upregulation of p21 and p27, downregulation of mutant p53 and anti-apoptotic IAP proteins, elevates intracellular ROS levels, reduces SOD activity, and induces apoptosis. Flavokawain C downregulates FABP4, induces autophagy in cancer cells, and activates the AMPK/mTOR pathway . Flavokawain C decreases the expression of glycolysis-related proteins GLUT1 and HK2, and inhibits glycolysis in nasopharyngeal carcinoma cells. Flavokawain C inhibits the activation of the EGFR/PI3K/Akt/mTOR signaling pathway and reduces the expression of *HSP90B1. Flavokawain C inhibits* angiogenesis by decreasing the expression of angiogenic proteins Ang-1 and VEGF in human umbilical vein endothelial cells. Flavokawain C increases γ-H2AX levels in cells, inhibits the phosphorylation of FAK, PI3K and AKT in cells, and induces DNA damage in cells. Flavokawain C exerts anti-tumor activity in multiple tumor xenograft mouse models. Flavokawain C is applicable to research related to colorectal cancer, colon adenocarcinoma, nephroblastoma, nasopharyngeal carcinoma and liver cancer .

HY-119906

Conglobatin FW-04-806	Natural Products Microorganisms Classification of Application Fields Disease Research Fields Cancer Source Classification	HSP Apoptosis
Conglobatin (FW-04-806), a macrolide dilactone, is isolated from the culture of Streptomyces conglobatus. Conglobatin is an orally active *Hsp90* inhibitor. Conglobatin can bind to the N-terminal domain of Hsp90 and disrupt Hsp90-Cdc37 complex formation. Conglobatin induces apoptosis in human breast cancer cells and esophageal squamous cell carcinoma cells, and exhibits antitumor activity in vivo .

HY-108486

Herbimycin A	Infection Quinones Microorganisms Classification of Application Fields Benzene Quinones Disease Research Fields Source Classification	Bacterial Antibiotic
Herbimycin A, an ansamycin antibiotic, acts as a Src family kinase inhibitor. Herbimycin A binds to the SH domain and inhibits the activity of p60 ^v-src and p210 ^BCR-ABL Herbimycin A inhibits Hsp90 and impairs recovery from heat shock. Herbimycin A exhibits antiangiogenic activity in endothelial cells in vitro.

HY-N14780

Pochonin D (+)-Pochonin D	Structural Classification Natural Products Microorganisms Source Classification	HSP Interleukin Related Enterovirus
Pochonin D ((+)-Pochonin D) is an inhibitor of heat shock protein 90 (Hsp90) with antiviral and anti-inflammatory activities. Pochonin D inhibits Hsp90, affects the homeostasis, folding and assembly processes of viral proteins, and reduces the replication capacity of viruses. Pochonin D reduces the infiltration of inflammatory cells, decreases the secretion of inflammatory cytokines such as TNF-α and IL-1β, and alleviates inflammatory responses. Pochonin D is a promising candidate for research on human rhinovirus (HRV) infection and cancer .

HY-N3417

Kongensin A 1 Publications Verification	Classification of Application Fields Euphorbiaceae Plants Inflammation/Immunology Disease Research Fields Croton kongensis Gagnep.	HSP RIP kinase Apoptosis Necroptosis
Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent *HSP90* inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications .

HY-15230R

Geldanamycin (Standard)	Quinones Structural Classification Microorganisms Benzene Quinones Source Classification	Reference Standards HSP Bacterial Influenza Virus Antibiotic
Geldanamycin (Standard) is the analytical standard of Geldanamycin. This product is intended for research and analytical applications. Geldanamycin is a *Hsp90* inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

HY-N15154

Tasiamide B	Natural Products Marine algae Marine natural products Source Classification	Cathepsin HSP
Tasiamide B is a Cathepsin D inhibitor, which is a linear peptide found in the marine cyanobacteria Symploca sp.. Tasiamide B is proved as a good template for the development of aspartic proteases inhibitors. Tasiamide B is effective against skin cancer by strongly interacting with the target protein *HSP90* .

HY-N1934R

Dihydroberberine (Standard)	Alkaloids Structural Classification other families Plants Isoquinoline Alkaloids Source Classification	Reference Standards Potassium Channel HSP
Dihydroberberine (Standard) is the analytical standard of Dihydroberberine. This product is intended for research and analytical applications. Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C)-induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy .

HY-N9722

Dehydroherbarin	Quinones Structural Classification Microorganisms Naphthalene Quinones Source Classification	HSP
Dehydroherbarin is a selective inhibitor targeting *HSP90α* with blood-brain barrier penetration. Dehydroherbarin interferes with key pathways of tumor cell survival by binding to HSP90α, while exerting moderate antibacterial and anti-hepatitis A virus activities and inhibiting tumor cell migration. Dehydroherbarin can be used in research on tumors such as breast cancer .

Cat. No.	Product Name	Chemical Structure

HY-10211S

Tanespimycin-d5

Tanespimycin-d₅ (17-AAG-d₅; NSC 330507-d₅; CP 127374-d₅) is the deuterium labeled Tanespimycin (HY-10211). Tanespimycin (17-AAG) is a potent HSP90 inhibitor with an IC₅₀ of 5 nM, having a 100-fold higher binding affinity for tumour cell derived HSP90 than normal cell derived HSP90 . Tanespimycin depletes cellular STK38/NDR1 and reduces STK38 kinase activity. Tanespimycin also downregulates the stk38 gene expression .

HY-13757S

Tamoxifen-d3 hydrochloride

Tamoxifen-d₃ hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .

HY-13757AS1

Tamoxifen-d3

Tamoxifen-d₃ is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .

HY-W778408

Tamoxifen-13C6

Tamoxifen- ¹³C₆ (ICI 47699- ¹³C₆) is the ¹³C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC₅₀ of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .

Cat. No.	Product Name		Classification

HY-115997

PROTAC HSP90 degrader BP3		PROTAC Synthesis
PROTAC HSP90 degrader BP3 is a potent and selective degradation of *HSP90* in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on *HSP90* protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-117395

PU-H54		Alkynes
PU-H54, a Grp94-selective inhibitor, can be used for the research of breast cancer. Hsp90 chaperone family, comprised in humans of four paralogs, Hsp90α, Hsp90β, Grp94 and Trap-1, has important roles in malignancy . PU-H54 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-169098

HSP90/LSD1-IN-1		Alkynes
HSP90/LSD1-IN-1 (compound 6) is a *HSP90/LSD1* dual inhibitor. HSP90/LSD1-IN-1 inhibits the proliferation of prostate cancer cell lines PC-3 and DU145, with GI₅₀ values of 0.24 and 0.30 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks